|
Post by lakers on Oct 11, 2016 17:49:45 GMT -5
Cannabis Companies Are Attracting Marijuana Investors With a Lot of Green FRIDAY, SEPTEMBER 16, 2016 AT 7:52 A.M. www.laweekly.com/news/cannabis-companies-are-attracting-marijuana-investors-with-a-lot-of-green-7381782Greiper says that the first substantial gains in the industry will be seen in the ag tech sector, since it is so closely tied to production; and in biotech, where companies like California-based Kalytera and British behemoth GW are making promising progress in using non-psychoactive elements of the cannabis plant to create pharmaceuticals targeted to combat ailments like multiple sclerosis and osteoporosis. Companies like these should benefit from the DEA’s recent decision to loosen restrictions around medical research of the plant. Last week, shares of GW Pharmaceuticals soared by 23%, up to nearly $100 a share, when the company announced that it had brought on Morgan Stanley to handle its fiscal affairs.
|
|
|
Post by lakers on Oct 11, 2016 16:13:00 GMT -5
FAQ: How will Technosphere technology be used by the licensee? "Technosphere technology is to be used as a vehicle to deliver regulated doses of a proprietary compound to treat a variety of medical conditions, including chronic pain, spasticity and inflammatory diseases such as rheumatoid arthritis." Fentanyl Maker Insys is Running CBD Clinical Trials NICK JIKOMES www.leafly.com/news/politics/fentanyl-maker-insys-running-cbd-clinical-trialsInsys Therapeutics, manufacturer of the synthetic opioid medication fentanyl, made headlines recently when it donated half a million dollars to the anti-cannabis legalization effort in Arizona. Fentanyl is a potent and highly addictive pain killer helping fuel the country’s opioid epidemic and skyrocketing overdose rates. Presumably, Insys is funding anti-legalization efforts because legal cannabis represents a threat to its bottom line: medical cannabis can be an alternative to opioids for pain management, and states with medical marijuana laws are seeing lower rates of opioid abuse. In addition, there is evidence that plant cannabinoids such as cannabidiol (CBD) may be useful for treating opioid dependence. So it seems clear why a pharmaceutical company specializing in the sale of a synthetic opioid would oppose cannabis legalization. But there’s more to it than that. Insys is currently running a number of clinical trials investigating the use of cannabis-based therapies for a variety of ailments. If you go to ClinicalTrials.gov, a website run by the NIH, you can search through ongoing clinical trials in the U.S. based on disease, location, and who’s funding it. If you search “Insys,” a couple of things pop out: they’re running lots of trials to study fentanyl, and lots of trials to study cannabidiol (CBD). CBD is non-psychoactive cannabinoid found in Cannabis, which we know is non-addictive and has wide-ranging therapeutic potential. Insys seems to know this as well, since they’re running CBD trials to treat everything from treatment-resistant child epilepsy to over-eating symptoms associated with Prader-Willi Syndrome (a rare genetic disorder). Search for, “Insys cannabidiol” on ClinicalTrials.gov and take a look for yourself. Insys is currently recruiting patients for a trial titled, “Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers”. We already know that medical cannabis can be effective for treating pain, and CBD may be one of the key compounds underlying this effect. Animal studies have also told us that CBD specifically may have analgesic properties, and that it may be useful for treating addiction.
So it’s no surprise that a corporation like Insys is funding the anti-legalization effort in Arizona. Legal adult-use cannabis represents a competitive threat to sales of their flagship narcotic (fentanyl) and the Cannabis-based therapies they’re trying to develop. Voters should take note of who is opposing legalization efforts in their state, and why. The case of Insys gives us yet another reason to support legalization this November. clinicaltrials.gov/ct2/results?term=Insys+cannabidiol&Search=Search1 Completed Cannabidiol Oral Solution in Pediatric Subjects With Treatment- Resistant Seizure Disorders Condition: Seizures Intervention: Drug: Cannabidiol Oral Solution 2 Not yet recruiting Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome Condition: Dravet Syndrome Interventions: Drug: Cannabidiol Oral Solution; Drug: Placebo Solution 3 Not yet recruiting Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome Condition: Lennox-Gastaut Syndrome Interventions: Drug: Cannabidiol Oral Solution; Drug: Placebo Solution 4 Enrolling by invitation Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder Condition: Seizures Intervention: Drug: Cannabidiol Oral Solution 5 Not yet recruiting Cannabidiol Oral Solution for The Treatment of Subjects With Prader-Willi Syndrome Condition: Prader-Willi Syndrome Interventions: Drug: Cannabidiol; Drug: Placebo 6 Active, not recruiting Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms Condition: Spasms, Infantile Intervention: Drug: Cannabidiol Oral Solution 7 Recruiting Cannabidiol and Emotional Stimuli Condition: Drug Addiction Interventions: Drug: Cannabidiol; Drug: Placebo 8 Recruiting Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers Condition: Pain Interventions: Drug: Cannabidiol; Drug: Placebo receptor.3rdhatch.com/wp-content/uploads/2016/10/rls-ops-October_2016_Generic.pdf
|
|
|
Post by lakers on Oct 11, 2016 2:40:10 GMT -5
|
|
|
Post by lakers on Oct 10, 2016 18:40:56 GMT -5
The in-game program has :
The turquoise avatar said: You've heard a lot about INSULIN The purple avatar said: What about OUTSULIN?
The purple bold headlines folow.
Mealtime INsulin has an OUTsulin part
Medical professionals often focus on how quickly mealtime insulin goes in and handles blood sugar spikes that can happen when you eat. It’s time for another discussion: how quickly it leaves the body, which you can think of as OUTsulin.
Afrezza is a rapid-acting mealtime insulin - Goes to work quickly (12-15 minutes rapid absorption rate) - Reaches maximum effect in about 53 minutes - Can stay active for up to 3 hours. By then your blood sugar returns to near pre-meal levels
That’s why you can appreciate the OUTsulin side of AFREZZA: INsulin that does its job, and then leaves.
The Dreamboat's actual size is printed with the text:
Afrezza is inhaled insulin. And yes, the Afrezza inhaler is this size. You could be using fewer needles everyday.
The yellow text says:
Could Afrezza be right for you ? Ask your doctor.
[Mnkd forgot to mention fast OUTsulin is equally important to avoid hypo which may cause such dangerous side effects as ...] Mike C., could you pls add this as laymen might not know ? You got to spell it out.
|
|
|
Post by lakers on Oct 9, 2016 18:53:37 GMT -5
Kevinmik 2h2 hours ago Kevinmik @kevinmik @mannkindcorp @ramsnfl @buffalobills great to see 2 full page center page ad that will catch many eye balls at the game Kevinmik 1h1 hour ago Kevinmik @kevinmik @mannkindcorp @ramsnfl @buffalobills program ads during the regular season will hopefully culminate with Afrezza Super Bowl TV Ad on 2/17/17
|
|
|
Post by lakers on Oct 9, 2016 18:17:30 GMT -5
MannKind Corporation (@mannkindcorp) 10/9/16, 2:17 PM Spotted ad @ramsnfl @buffalobills game day! pic.twitter.com/w2WLzZRU5K
As promised.
|
|
|
Epi
Oct 5, 2016 18:56:01 GMT -5
cm5 likes this
Post by lakers on Oct 5, 2016 18:56:01 GMT -5
U.S. government health plans spent over $1 billion on EpiPens over five years www.reuters.com/article/us-mylan-epipen-cms-idUSKCN1252S7By Bill Berkrot U.S. government health plans spent more than $1 billion on Mylan NV's EpiPen emergency allergic reaction treatment between 2011 and 2015, according to figures released by the Centers for Medicare and Medicaid Services on Wednesday. Mylan is under scrutiny for raising prices on the lifesaving EpiPen sixfold in less than a decade, making the devices unaffordable for a growing number of families. U.S. lawmakers and prosecutors are also investigating what impact Mylan's EpiPen pricing has had on government-funded health programs. CMS, in response to a request from U.S. Senator Amy Klobuchar of Minnesota, said in a letter that the Medicaid plan for the poor spent $797 million on EpiPen in the five-year period, including rebates provided by Mylan, or $960 million before rebates. Costs for the Medicare Part D program for the elderly was nearly $335 million, a figure that does not reflect rebates.
Klobuchar and other lawmakers contend that Mylan underpaid rebates to state Medicaid programs by misclassifying EpiPen as a generic instead of a branded drug. The Medicaid rebate for a generic is 13 percent compared with a minimum 23.1 percent for a branded drug.
CMS said it could not determine how much the government is owed for EpiPens, but reiterated its view that Mylan had misclassified the product. "CMS has, on multiple occasions, provided guidance to the industry and Mylan on the proper classification of drugs and has expressly told Mylan that the product is incorrectly classified," the agency said. Mylan has said it complied with CMS rules. On Wednesday, it noted that the classification of EpiPen for Medicaid rebates had been made in 1997, a decade before it acquired the product. New CMS rules that took effect this year allow companies to clarify any classification issues for a product like EpiPen, with companies asked to submit their requests by April 1, 2017. "It would be premature to comment further on this issue until the CMS process has concluded," Mylan said. Klobuchar in a statement called for "clear answers on how deep this misclassification goes, how much it has cost taxpayers across the country, how many other drugs may be misclassified, and how we get that money back."Mylan Chief Executive Heather Bresch was blasted by lawmakers during a congressional hearing last month for raising the list price for a pair of EpiPens to more than $600 this year. It cost about $100 in 2007, when Mylan acquired the product.
|
|
|
Epi
Oct 5, 2016 18:41:28 GMT -5
cm5 likes this
Post by lakers on Oct 5, 2016 18:41:28 GMT -5
|
|
|
Post by lakers on Oct 4, 2016 19:05:11 GMT -5
Mike Castagna (@castagna2011) 10/4/16, 2:12 PM @l_Piccioli Pittsburgh win has shocked me. Well makes for an interesting season! Rooting for west coast @laramsfanzone BC I live in CA
Luigi Piccioli (@l_Piccioli) 10/4/16, 9:32 AM @castagna2011 Still feeling that spanking your Eagles gave my Bears. Damn you Mike! LOL
Interestingly, Today Twit exchange identified 3 NFL teams I mentioned.
|
|
|
Post by lakers on Oct 4, 2016 17:23:32 GMT -5
Could someone please post pictures of the printed programs showing Afrezza infomercial for the MLB playoffs. First up is American League wild-card teams. Baltimore Orioles (BAL 5, TOR 2) at Toronto Blue Jays (TOR 2, BOS 1) Date: Tuesday, Oct. 4 Time: 8 p.m. ET Venue: Rogers Centre in Toronto m.mlb.com/postseason-scheduleTuesday, October 4 8:00 PM ALWC Orioles @ Blue Jays Tillman (16-6) at Stroman (9-10) TBS / SNET Wednesday, October 5 8:00 PM NLWC Giants @ Mets Bumgarner (15-9) at Syndergaard (14-9) ESPN Thursday, October 6 4:30 PM ALDS Gm 1 AL Wild Card @ Rangers TBD at TBD TBS 8:00 PM ALDS Gm 1 Red Sox @ Indians Porcello (22-4) at Bauer (12-8) TBS Friday, October 7 1:00 PM ALDS Gm 2 AL Wild Card @ Rangers TBD at TBD TBS 4:30 PM ALDS Gm 2 Red Sox @ Indians Price (17-9) at Kluber (18-9) TBS 5:30 PM NLDS Gm 1 Dodgers @ Nationals Kershaw (12-4) at TBD FS1 9:00 PM NLDS Gm 1 NL Wild Card @ Cubs TBD at TBD FS1 Saturday, October 8 4:00 PM NLDS Gm 2 Dodgers @ Nationals Hill (12-5) at TBD FS1 8:00 PM NLDS Gm 2 NL Wild Card @ Cubs TBD at TBD MLBN Sunday, October 9 4:00 PM ALDS Gm 3 Indians @ Red Sox Tomlin (13-9) at TBD TBS 7:30 PM ALDS Gm 3 Rangers @ AL Wild Card TBD at TBD TBS Monday, October 10 TBD NLDS Gm 3 Nationals @ Dodgers TBD at Maeda (16-11) FS1 / MLBN TBD NLDS Gm 3 Cubs @ NL Wild Card TBD at TBD FS1 / MLBN TBD ALDS Gm 4* Indians @ Red Sox TBD at TBD TBS TBD ALDS Gm 4* Rangers @ AL Wild Card TBD at TBD TBS * if necessary Tuesday, October 11 TBD NLDS Gm 4* Nationals @ Dodgers TBD at TBD FS1 TBD NLDS Gm 4* Cubs @ NL Wild Card TBD at TBD FS1 * if necessary Wednesday, October 12 TBD ALDS Gm 5* Red Sox @ Indians TBD at TBD TBS TBD ALDS Gm 5* AL Wild Card @ Rangers TBD at TBD TBS * if necessary Thursday, October 13 TBD NLDS Gm 5* Dodgers @ Nationals TBD at TBD FS1 TBD NLDS Gm 5* NL Wild Card @ Cubs TBD at TBD FS1 * if necessary Friday, October 14 TBD ALCS Gm 1 AL Lower Seed @ AL Higher Seed TBD at TBD TBS Saturday, October 15 TBD NLCS Gm 1 NL Lower Seed @ NL Higher Seed TBD at TBD FOX / FS1 TBD ALCS Gm 2 AL Lower Seed @ AL Higher Seed TBD at TBD TBS Sunday, October 16 TBD NLCS Gm 2 NL Lower Seed @ NL Higher Seed TBD at TBD FOX / FS1 Monday, October 17 TBD ALCS Gm 3 AL Higher Seed @ AL Lower Seed TBD at TBD TBS Tuesday, October 18 TBD NLCS Gm 3 NL Higher Seed @ NL Lower Seed TBD at TBD FOX / FS1 TBD ALCS Gm 4 AL Higher Seed @ AL Lower Seed TBD at TBD TBS Wednesday, October 19 TBD NLCS Gm 4 NL Higher Seed @ NL Lower Seed TBD at TBD FOX / FS1 TBD ALCS Gm 5* AL Higher Seed @ AL Lower Seed TBD at TBD TBS * if necessary Thursday, October 20 TBD NLCS Gm 5* NL Higher Seed @ NL Lower Seed TBD at TBD FOX / FS1 * if necessary Friday, October 21 TBD ALCS Gm 6* AL Lower Seed @ AL Higher Seed TBD at TBD TBS * if necessary Saturday, October 22 TBD NLCS Gm 6* NL Lower Seed @ NL Higher Seed TBD at TBD FOX / FS1 TBD ALCS Gm 7* AL Lower Seed @ AL Higher Seed TBD at TBD TBS * if necessary Sunday, October 23 TBD NLCS Gm 7* NL Lower Seed @ NL Higher Seed TBD at TBD FOX / FS1 * if necessary Tuesday, October 25 TBD WS Gm 1 NL Champion @ AL Champion TBD at TBD FOX Wednesday, October 26 TBD WS Gm 2 NL Champion @ AL Champion TBD at TBD FOX Friday, October 28 TBD WS Gm 3 AL Champion @ NL Champion TBD at TBD FOX Saturday, October 29 TBD WS Gm 4 AL Champion @ NL Champion TBD at TBD FOX Sunday, October 30 TBD WS Gm 5* AL Champion @ NL Champion TBD at TBD FOX * if necessary Tuesday, November 1 TBD WS Gm 6* NL Champion @ AL Champion TBD at TBD FOX * if necessary Wednesday, November 2 TBD WS Gm 7* NL Champion @ AL Champion TBD at TBD FOX
|
|
|
Post by lakers on Oct 4, 2016 14:43:46 GMT -5
|
|
|
Post by lakers on Oct 4, 2016 13:52:57 GMT -5
Cj: I'm curious as to what "rights" Sanofi holds in regards to MNKD tech, patents, and property as "collateral." Do you have a moment to elaborate on this? I've never heard this before. Mahalo. I know there are others here who know all the details better than I do, but from what I understand, SNY holds the patents and tech for Afrezza and at least the Valencia head quarters as collateral against the loan. "The loan" of course being all money SNY blew and accomplished nothing with. Slightly ironic. Yes. The ~$75M loan is dead money to Sny until 2024 anyway, albeit 8% interest if Mnkd will still be an independent entity. That's why I think any settlement will likely include a loan forgiveness. This will lift the lien from those assets. Mnkd can then use those freed assets as collaterals for future financing or sell the Valencia HQ. Sny will likely offer this first (gimme) plus additional comp.
|
|
|
Post by lakers on Oct 3, 2016 21:46:02 GMT -5
There is pre-clinical, then whatever clinical trial(s) that are needed to gather IND data. It seems that they are adhering to the timeline published earlier. Most likely Mnkd will partner up for EpiHale as the FDA approval process is expensive. It can't go alone. Mnkd needs to look for a partner now as it takes time. It will have more leverage w/ an IND in hand and ample cash. This is where Sny settlement could help. I think PAHale holds good potential. The mkt is dominated by UT whose inhaling device is a huge bong while PAHale's PD/PK profile is better. Matt has been traveling in the last 2 weeks, perhaps busy negotiating something?
|
|
|
Post by lakers on Oct 3, 2016 18:52:17 GMT -5
1-5 except 2 are known by most to certain degree. All investors knew that Sny and Mnkd have been negotiating. I don't know whether it will be with JDRF. There are 32 NFL teams. I was able to name 4 specific teams. Does that lend any truth? Judge for yourself. Someone from ST received an email from Mike and he does mention NFL marketing - stocktwits.com/message/63922919Mike C.'s email confirmed NFL marketing. I even provided four NFL team names. What more do you want? EpiHale partner ? Settlement ? charts.stocktwits.com/production/original_63922919.?1475531269
|
|
|
Post by lakers on Oct 3, 2016 15:49:10 GMT -5
NFL game day pamphlet is a surprise in addition to MLB playoffs. It makes sense as NFL is the largest market in U.S. Mgmt must be confident about the funding. These Mktgs are not cheap. Anything more you can provide on the "comarketing" front? Will it be with JDRF? I know they get some free marketing exposure. 1-5 except 2 are known by most to certain degree. All investors knew that Sny and Mnkd have been negotiating. I don't know whether it will be with JDRF. There are 32 NFL teams. I was able to name 4 specific teams. Does that lend any truth? Judge for yourself.
|
|